Liraglutide vs Lixisenatide: evidence, status and structure
A side-by-side look at Liraglutide and Lixisenatide, using the data on each VALREXA profile. Neither comparison is a recommendation.
Key differences
- Both sit at the same evidence level: Approved use.
- Both have the same U.S. status category: FDA-approved.
- Lixisenatide is about 1.3× heavier than Liraglutide (~4,858 vs ~3,751.2 Da).
| Liraglutide | Lixisenatide | |
| Research class | Metabolic Research | Metabolic Research |
| Human evidence | Approved use | Approved use |
| U.S. status | FDA-approved (Victoza, Saxenda) | FDA-approved only within Soliqua; stand-alone Adlyxin discontinued (2023) |
| 2026 compounding decision | — | — |
| Amino acids | 31 (modified) | 44 |
| Molecular weight | ~3,751.2 Da | ~4,858 Da |
| Formula | C₁₇₂H₂₆₅N₄₃O₅₁ | C₂₁₅H₃₄₇N₆₁O₆₅S |
| Sequence | — | Exendin-4-based 44-residue analogue |
| Research period | 2010 | 2016 |
| Safety summary | FDA-approved; labels include a boxed warning about thyroid C-cell tumors seen in rodents. | FDA-approved in combination with insulin glargine. Common side effects are nausea and vomiting. |
How they differ
Both are daily GLP-1 receptor agonists for type 2 diabetes, but they sit at opposite ends of the daily timeline. Liraglutide (Victoza) acts through the whole day and is also approved for weight management at a higher dose (Saxenda). Lixisenatide is shorter-acting, with its strongest effect on slowing the stomach at mealtimes. Lixisenatide is now sold in the U.S. only inside the combination pen Soliqua; liraglutide remains available on its own.
What each one is
Liraglutide: Once-daily GLP-1 receptor agonist with a fatty-acid chain. Molecular weight, sequence, research history, human evidence and regulatory status.
Lixisenatide: A short-acting GLP-1 receptor agonist for type 2 diabetes, now available only in a combination pen. Molecular weight, sequence, research history, human evidence and regulatory status.
Educational reference only. Nothing here is medical advice, a treatment recommendation, or dosing or sourcing guidance. Report an error.